P took a drug, this drug caused him to develop a priapism, a prolonged painful erection, which ultimately required surgery and left him impotent. During trial, P sought to introduce a letter from a Dr. Paul Leber, Director of the FDA's Division of Neuropharmacological Drug Products recommending that a boxed warning be included on the drug's label to emphasize the risk of priapism and the potential need for surgery and the threat of impotence. D objected on hearsay grounds and the court issued its ruling. P also sought to introduce evidence of a meeting between D and Dr. Rubin Bressler, two of D's employees, and five outside medical experts related to a Tuscon meeting regarding what should D tell treating physicians regarding the possibility of priapism and what warnings should appropriately accompany the drug. P sought admission of these tapes under 801(d)(2) as an admission by D.

This section contains the nature of the case and procedural background.

The legal issues presented in this case will be displayed here.

The court's holding and decision will be displayed here.

Legal analysis from Dean's Law Dictionary will be displayed here.